- Home
- CD vs AVIR Comparison
CD vs AVIR Comparison
Compare CD & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CD | AVIR |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | 13 | N/A |
| Industry | Computer Software: Programming Data Processing | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 382.5M | 399.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CD | AVIR |
|---|---|---|
| Price | $3.14 | $4.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 409.5K | 359.4K |
| Earning Date | 08-31-2023 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.01 | $2.78 |
| 52 Week High | $14.10 | $6.45 |
Technical Indicators
Market Signals| Indicator | CD | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 28.24 | 53.12 |
| Support Level | $3.09 | $4.14 |
| Resistance Level | $5.20 | $5.04 |
| Average True Range (ATR) | 0.52 | 0.23 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 6.19 | 63.27 |
Price Performance
Historical ComparisonAbout CD Chaince Digital Holdings Inc. Ordinary Shares
Chaince Digital Holdings Inc is digital fintech company providing access to the growing AI-powered infrastructure, blockchain, and digital assets. Its three core business lines include: blockchain and digital asset solutions, AI and HPC infrastructure, developing liquid cooling solutions for AI data centers and comprehensive financial services through Chaince Securities,LLC a FINRA-registered broker-dealer, and RIA.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.